1Harris GJ, Lewis RF, Satlin A, et al. Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzhimer disease: a promising alternative to nuclear medicine. AJNR Am J Neuroradiol,1998,19(9):1727
2Maas LC, Harris GJ, Satlin A, et al. Regional cerebral blood volume measured by dynamic susceptibility contrast MR imaging in Alzheimer's disease: a principal components analysis. J Magn Reson Imaging,1997,7(1):215
3Braak H, Braak E. Neuropathological stages of Alzheimer's disease. In: de Leon MJ, ed. An atlas of Alzheimer's disease. New York, NY: Parthenon,1999,57
4Charpentier P, Lavenu I, Defebvre L, et al. Alzheimer's disease and frontotemporal dementia are differentiated by discriminant analysis applied to Tc HmPAO SPECT data. J Neurol Neurosurg psychiatry,2000,69(5):661
5McMahon PM, Araki SS, Neumann PJ, et al. Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease. Radiology,2000,217(1):58
6Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA,2001,286(17):2120
7Pietrini P, Alexander GE, Furey ML, et al. Cerebral metabolic response to passive audiovisual stimulation in patients with Alzheimer's disease and healthy volunteers assessed by PET. J Nucl Med,2000,41(4): 575
8Small SA, Nava AS, Perera GM, et al. Evaluating the function of hippocampal subregions with high-resolution MRI in Alzheimer's disease and aging. Microsc Res Tech,2000,51(1):101
9Johnson SC, Saykin AJ, Baxter LC, et al. The relationship between fMRI activation and cerebral atrophy: comparison of normal aging and Alzheimer disease. Neuroimage, 2000,11(3):179
10Shonk TK, Moats RA, Gifford P, et al. Probable Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology,1997,203(3):829
二级参考文献12
1Duvernoy HM. The human hippocampus: an atlas of applied anatomy. Muchen: JF Bergmann Verlag, 1988. 31-45.
2Insausti R, Juttonen K, Soininen H, et al. MR volumetric analysis of the human entorhinal, perirhinal, and temporolar cortices. AJNR, 1998, 19: 659-671.
3Insausti R, Tunón T, Sobreviela T, et al. The human entorhinal cortex: acytoarchitectonic analysis. J Comput Neurol,1995,355:171-198.
4Jost BC,Grossberg GT. The natural history of Alzheimer′s disaese:a brain bank study. J Am Geriatr Soc,1995,43:1248-1255.
5Braak H,Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol, 1991,82: 239-259.
6Kazee AM, Eskin TA, Lapham LW, et al. Clinical pathologic correlates in Alzheimer′s disease: assessment of clinical and pathologic diagnosis criteria. Alz Dis Assoc Disord,1993,3:152-164.
7Launer LJ, Scheltens P, Lindeboom J, et al. Medial temporal lobe atrophy in an open population of very old persons: cognitive, brain atrophy, and sociomedical correlates. Neurology,1995, 45:747-752.
8Frisoni GB, Beltramello A, Weiss C, et al. Linear measures of atrophy in mild Alzheimer disease. AJNR, 1996, 17:913-923.
9Juottonen K,Laakso MP,Partanen K,et al. Comparative MR analysis of the entorhinal cortex and hippocampus in diagnosing Alzheimer′s disease. AJNR,1999,20:139-144.
10Xu Y,Jack CR Jr,O′Brien PC, et al. Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD.Neurology,2000,54:1760-1767.
1De la Monte SM, Tong M, Lester-Coll N, et al. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease [J]. Alzheimers Dis, 2006, 10 (1) : 89 -109.
2De la Torte JC. Pathophysiology of neuronal energy crisis in Alzheimer's disease [ J]. Neurodegener Dis. 2008,5 ( 3-4 ) : 126 - 132.
3Blass JP, Sheu RK, Gibson GE. Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise [ J ]. Ann New York AcAD Sci, 2000,903 : 204 - 221.
5Garcia-Alloza M, Borrelli LA, Rozkalne A, et al. Baeskai. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model[ J ]. J Neuruchem, 2007,102 (4) : 1095 - 1104.
6Begum AN, Jones MR, Lim GP, et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease [ J]. J Pharmacol Exp Ther,2008,326 (1) :196 -208.
7Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin" : From kitchen to clinic[ J]. Biochem Pharmacol,2008, 75(4) :787 -809.
8Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neumdegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases[ J]. Int J Biochem Cell Biol,2009,41 (1) :40 -59.
9Siwak DR,Shishodia S, Aggarwal BB,et al. Cureumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-aetivated/extracellular signal-regulated protein kinase pathway and the Akt pathway[J]. Cancer,2005.104(4) :879 -890.
